Vancouver-based DelMar Pharmaceuticals [DMPI] is developing new drug candidates targeting orphan cancer indications representing market opportunities in the $100s of millions in North America and potentially billions of dollars worldwide. Promising data announced in 2012 with follow ups scheduled at various healthcare conferences this year coincided with the company’s recent listing on the OTCQB, which commenced Q1-2013. OneMedRadio spoke with the Del Mar CEO about these milestones.
Browsing: val-083
DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.